Liom Fuels Health Tech Revolution with €13.9M for Non-Invasive Glucose Monitor
December 25, 2025, 9:50 am
Location: South Korea
Employees: 10001+
Founded date: 1938
Total raised: $6.4B
Swiss HealthTech innovator Liom secured €13.9 million, bringing total funding to €67.6 million. The company is developing a revolutionary non-invasive, calibration-free glucose monitoring wearable. This technology miniaturizes Raman spectroscopy, enabling smartwatch-sized devices with superior performance and long battery life. Liom aims for a 2028 market launch, providing real-time metabolic health insights. Marc Maurer, former co-CEO of On Running, joins Liom's board, infusing consumer product expertise. This funding underscores strong investor confidence in continuous health monitoring and preventive care solutions, poised to disrupt the wider wearable market and improve quality of life for many. The innovation pushes health tech beyond traditional clinical settings, empowering individuals with direct, actionable physiological data.
A significant investment boosts the future of health monitoring. Swiss startup Liom recently closed a €13.9 million extension to its Series A funding round. This brings their total Series A capital to €40.8 million. Overall funding now reaches an impressive €67.6 million. The company, founded in 2017, focuses on preventive and personalized health. Its core innovation: a non-invasive glucose-monitoring wearable.
Investors signal strong confidence in this new frontier. Red Bull Ventures participated in the latest round. Marc Maurer, former co-CEO of successful footwear brand On Running, also joined. Other key participants include Melih Odemis, former co-founder of Yemeksepeti, and Alejo Costa Ribalta of CRB Health Tech. This diverse backing underscores broad belief in Liom's disruptive potential.
Liom’s technology represents a major leap. They have miniaturized proprietary Raman spectroscopy. This platform measures glucose non-invasively. Crucially, it requires no calibration needles. This sets it apart from existing continuous glucose monitors. Over 130 subjects have validated the method in trials.
The miniaturization breakthrough is profound. It dramatically increases light throughput. Performance exceeds even large lab-scale devices. Liom’s solution is 12 times more efficient. This enables a smartwatch-fitting form factor. It also supports over 24 hours of battery life. Manufacturability at scale becomes feasible. These advancements resolve critical technical barriers. Non-invasive, calibration-free glucose monitoring is now closer to consumers.
The company plans its first product launch for 2028. This wearable will offer comprehensive metabolic health insights. Users will gain real-time biophysical feedback. This empowers better understanding of nutrition and movement. It promotes a healthier lifestyle without invasive procedures. Future capabilities envision measuring other biomarkers. These include lipids, proteins, ketones, hydration, and lactate. Liom’s light- and AI-based technology is adaptable.
Strategic leadership strengthens Liom’s path forward. Marc Maurer joins as both an investor and a Board member. His background at On Running is invaluable. That company boasts an €11.8 billion valuation. Maurer brings deep expertise in product development and consumer value creation. His skills cover branding and marketing. This is vital at the intersection of health, fitness, and consumer products. He will guide Liom from research and development into commercialization. His insights target mass adoption. Current microneedle CGM devices have limitations. Liom aims to overcome these.
The broader European HealthTech landscape mirrors this trend. Venture capital increasingly flows into wearables, biosensing, and preventive care. Investors favor technologies offering continuous health insights. These solutions extend beyond traditional clinical settings.
Consider other 2025 funding rounds. Sava Technologies Ltd., based in London, secured €16.6 million in Series A funding. This supports regulatory approval and commercialization of its molecular wearable sensors. Its total funding approaches €28 million. Lucis, another innovator, raised €7.2 million in Seed funding. They aim to expand their biomarker-based health analytics platform across Europe. GlycanAge secured €7.4 million for its glycan-based diagnostics. This scales preventive aging care.
Collectively, these investments highlight a vibrant sector. Approximately €31 million funneled into continuous monitoring solutions this year. Personalised metabolic insight tools also draw significant capital. Preventive diagnostics are a key focus. Liom’s non-invasive glucose wearable stands at the forefront of this movement.
The market for wearables is vast. Apple Watch, Samsung Galaxy Watch, Fitbit, Garmin, Whoop, and Oura define it. Yet, sensor-level innovation has been scarce for a decade. Liom’s technology promises to disrupt this stagnation. It offers a fresh wave of innovation. This could significantly expand the entire wearable market. Access to needle-free glucose measurements can profoundly impact daily life. It allows everyone to understand their body better. This directly contributes to a higher quality of life.
Liom is not just developing a product. It is building a platform for future health. The ability to monitor multiple biomarkers non-invasively holds immense promise. This approach personalizes health management like never before. It empowers individuals with critical data about their own bodies. This is the future of preventive healthcare. Liom positions itself as a leader in this evolving paradigm.
The capital infusion ensures Liom's continued development. It accelerates the journey to market launch. The goal is clear: make advanced health monitoring accessible. Non-invasive, real-time insights for all. This vision drives Liom’s innovation and investment. The health tech revolution is underway. Liom is at its vanguard.
A significant investment boosts the future of health monitoring. Swiss startup Liom recently closed a €13.9 million extension to its Series A funding round. This brings their total Series A capital to €40.8 million. Overall funding now reaches an impressive €67.6 million. The company, founded in 2017, focuses on preventive and personalized health. Its core innovation: a non-invasive glucose-monitoring wearable.
Investors signal strong confidence in this new frontier. Red Bull Ventures participated in the latest round. Marc Maurer, former co-CEO of successful footwear brand On Running, also joined. Other key participants include Melih Odemis, former co-founder of Yemeksepeti, and Alejo Costa Ribalta of CRB Health Tech. This diverse backing underscores broad belief in Liom's disruptive potential.
Liom’s technology represents a major leap. They have miniaturized proprietary Raman spectroscopy. This platform measures glucose non-invasively. Crucially, it requires no calibration needles. This sets it apart from existing continuous glucose monitors. Over 130 subjects have validated the method in trials.
The miniaturization breakthrough is profound. It dramatically increases light throughput. Performance exceeds even large lab-scale devices. Liom’s solution is 12 times more efficient. This enables a smartwatch-fitting form factor. It also supports over 24 hours of battery life. Manufacturability at scale becomes feasible. These advancements resolve critical technical barriers. Non-invasive, calibration-free glucose monitoring is now closer to consumers.
The company plans its first product launch for 2028. This wearable will offer comprehensive metabolic health insights. Users will gain real-time biophysical feedback. This empowers better understanding of nutrition and movement. It promotes a healthier lifestyle without invasive procedures. Future capabilities envision measuring other biomarkers. These include lipids, proteins, ketones, hydration, and lactate. Liom’s light- and AI-based technology is adaptable.
Strategic leadership strengthens Liom’s path forward. Marc Maurer joins as both an investor and a Board member. His background at On Running is invaluable. That company boasts an €11.8 billion valuation. Maurer brings deep expertise in product development and consumer value creation. His skills cover branding and marketing. This is vital at the intersection of health, fitness, and consumer products. He will guide Liom from research and development into commercialization. His insights target mass adoption. Current microneedle CGM devices have limitations. Liom aims to overcome these.
The broader European HealthTech landscape mirrors this trend. Venture capital increasingly flows into wearables, biosensing, and preventive care. Investors favor technologies offering continuous health insights. These solutions extend beyond traditional clinical settings.
Consider other 2025 funding rounds. Sava Technologies Ltd., based in London, secured €16.6 million in Series A funding. This supports regulatory approval and commercialization of its molecular wearable sensors. Its total funding approaches €28 million. Lucis, another innovator, raised €7.2 million in Seed funding. They aim to expand their biomarker-based health analytics platform across Europe. GlycanAge secured €7.4 million for its glycan-based diagnostics. This scales preventive aging care.
Collectively, these investments highlight a vibrant sector. Approximately €31 million funneled into continuous monitoring solutions this year. Personalised metabolic insight tools also draw significant capital. Preventive diagnostics are a key focus. Liom’s non-invasive glucose wearable stands at the forefront of this movement.
The market for wearables is vast. Apple Watch, Samsung Galaxy Watch, Fitbit, Garmin, Whoop, and Oura define it. Yet, sensor-level innovation has been scarce for a decade. Liom’s technology promises to disrupt this stagnation. It offers a fresh wave of innovation. This could significantly expand the entire wearable market. Access to needle-free glucose measurements can profoundly impact daily life. It allows everyone to understand their body better. This directly contributes to a higher quality of life.
Liom is not just developing a product. It is building a platform for future health. The ability to monitor multiple biomarkers non-invasively holds immense promise. This approach personalizes health management like never before. It empowers individuals with critical data about their own bodies. This is the future of preventive healthcare. Liom positions itself as a leader in this evolving paradigm.
The capital infusion ensures Liom's continued development. It accelerates the journey to market launch. The goal is clear: make advanced health monitoring accessible. Non-invasive, real-time insights for all. This vision drives Liom’s innovation and investment. The health tech revolution is underway. Liom is at its vanguard.